Home  /  Resource Library  /  Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRP, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study

Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRP, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study

Results of a study investigating amulirafusp alfa for treatment of relapsed non-hodgkin lymphomas.